{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:22:42Z","timestamp":1786994562339,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microvascular Research"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.mvr.2022.104401","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T01:53:46Z","timestamp":1655776426000},"page":"104401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Intravitreal injection of EV11, a novel aryl ketone amide, inhibits choroidal neovascularization via AKT\/ERK1\/2 pathway"],"prefix":"10.1016","volume":"143","author":[{"given":"Hongyu","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghe","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiliang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mvr.2022.104401_bb0005","first-page":"12","article-title":"Novel targeted therapies for metastatic thyroid cancer-a comprehensive review","author":"Al-Jundim","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.mvr.2022.104401_bb0010","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of interavitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina (Philadelphia, Pa.) [J]"},{"key":"10.1016\/j.mvr.2022.104401_bb0015","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006928","article-title":"Macular translocation for neovascular age-related macular degeneration","volume":"8","author":"Eandi","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.mvr.2022.104401_bb0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14737140.2019.1559058","article-title":"Sorafenib: key lessons from over 10 years of experience","volume":"19","author":"Escudier","year":"2019","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.mvr.2022.104401_bb0025","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40259-013-0049-y","article-title":"Sorafenib and thyroid cancer","volume":"27","author":"Fallahi","year":"2013","journal-title":"BioDrugs"},{"key":"10.1016\/j.mvr.2022.104401_bb0030","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2174\/0929867326666190726121711","article-title":"Pharmacological advances in the treatment of age-related macular degeneration","volume":"27","author":"Gil-Mart\u00ednez","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.mvr.2022.104401_bb0035","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","article-title":"Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial","volume":"5","author":"He","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.mvr.2022.104401_bb0040","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mvr.2022.104401_bb0045","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/cac2.12110","article-title":"Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis","volume":"40","author":"Hou","year":"2020","journal-title":"Cancer Commun."},{"key":"10.1016\/j.mvr.2022.104401_bb0050","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5489476","article-title":"Intravitreal injection of hydrogen peroxide induces acute retinal degeneration, apoptosis, and oxidative stress in mice","volume":"2018","author":"Huang","year":"2018","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.mvr.2022.104401_bb0055","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.ejca.2010.06.121","article-title":"Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET","volume":"46","author":"Hutson","year":"2010","journal-title":"Eur. J. Cancer (Oxford, England : 1990)"},{"key":"10.1016\/j.mvr.2022.104401_bb0060","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1167\/iovs.16-19300","article-title":"Intravitreal injection of proinsulin-loaded microspheres delays photoreceptor cell death and vision loss in the rd10 mouse model of retinitis pigmentosa","volume":"57","author":"Isiegas","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.mvr.2022.104401_bb0065","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/156800908783497122","article-title":"AKT signaling in regulating angiogenesis","volume":"8","author":"Jiang","year":"2008","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.mvr.2022.104401_bb0070","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/nprot.2013.135","article-title":"Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice","volume":"8","author":"Lambert","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.mvr.2022.104401_bb0075","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1517\/13543784.2013.802769","article-title":"Sorafenib for ovarian cancer","volume":"22","author":"Leone Roberti Maggiore","year":"2013","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.mvr.2022.104401_bb0080","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13287-020-02064-0","article-title":"Human umbilical cord mesenchymal stem cell-derived exosomal miR-27b attenuates subretinal fibrosis via suppressing epithelial-mesenchymal transition by targeting HOXC6","volume":"12","author":"Li","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.mvr.2022.104401_bb0085","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.mvr.2022.104401_bb0090","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1517\/13543784.2012.665872","article-title":"Sorafenib in melanoma","volume":"21","author":"Mangana","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.mvr.2022.104401_bb0095","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1016\/j.ophtha.2020.01.029","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"127","author":"Martin","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mvr.2022.104401_bb0100","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0161-6420(99)90167-7","article-title":"Surgical removal of subfoveal choroidal neovascularization in age-related macular degeneration","volume":"106","author":"Merrill","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mvr.2022.104401_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100906","article-title":"Incomplete response to anti-VEGF therapy in neovascular AMD: exploring disease mechanisms and therapeutic opportunities","volume":"82","author":"Mettu","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.mvr.2022.104401_bb0110","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.preteyeres.2013.09.003","article-title":"Photodynamic therapy for polypoidal choroidal vasculopathy","volume":"37","author":"Nowak-Sliwinska","year":"2013","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.mvr.2022.104401_bb0115","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/ajh.25198","article-title":"Sorafenib combined with 5-azacytidine in older patients with untreated FLT3-ITD mutated acute myeloid leukemia","volume":"93","author":"Ohanian","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.mvr.2022.104401_bb0120","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/path.4138","article-title":"Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL","volume":"229","author":"Pennarun","year":"2013","journal-title":"J. Pathol."},{"key":"10.1016\/j.mvr.2022.104401_bb0125","first-page":"21","article-title":"Neovascular age-related macular degeneration: therapeutic management and new-upcoming approaches","author":"Ricci","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mvr.2022.104401_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(19)30735-1","article-title":"Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study","volume":"21","author":"Rini","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.mvr.2022.104401_bb0135","first-page":"513","article-title":"The diagnosis and treatment of age-related macular degeneration","volume":"117","author":"Stahl","year":"2020","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.mvr.2022.104401_bb0140","doi-asserted-by":"crossref","first-page":"25509","DOI":"10.1038\/srep25509","article-title":"A novel small molecule ameliorates ocular neovascularisation and synergises with anti-VEGF therapy","volume":"6","author":"Sulaiman","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mvr.2022.104401_bb0145","doi-asserted-by":"crossref","first-page":"6014","DOI":"10.1167\/iovs.18-25213","article-title":"Light-induced lipocalin 2 facilitates cellular apoptosis by positively regulating reactive oxygen Species\/Bim signaling in retinal degeneration","volume":"59","author":"Tang","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.mvr.2022.104401_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197670","article-title":"The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-a cost-effectiveness analysis from a societal perspective","volume":"13","author":"Van Asten","year":"2018","journal-title":"PloS one"},{"key":"10.1016\/j.mvr.2022.104401_bb0155","article-title":"Laser photocoagulation for neovascular age-related macular degeneration","volume":"44","author":"Virgili","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.mvr.2022.104401_bb0160","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.jhep.2018.07.004","article-title":"Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer","volume":"69","author":"Wang","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.mvr.2022.104401_bb0165","first-page":"1857","article-title":"Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review","volume":"10","author":"Yang","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.mvr.2022.104401_bb0170","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.canlet.2018.03.037","article-title":"Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells","volume":"425","author":"Zanotto-Filho","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.mvr.2022.104401_bb0175","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1517\/13543784.2012.699039","article-title":"Sorafenib in non-small cell lung cancer","volume":"21","author":"Zhang","year":"2012","journal-title":"Expert Opin. Investig. Drugs"}],"container-title":["Microvascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026286222000917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026286222000917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:00:45Z","timestamp":1758434445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026286222000917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":35,"alternative-id":["S0026286222000917"],"URL":"https:\/\/doi.org\/10.1016\/j.mvr.2022.104401","relation":{},"ISSN":["0026-2862"],"issn-type":[{"value":"0026-2862","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravitreal injection of EV11, a novel aryl ketone amide, inhibits choroidal neovascularization via AKT\/ERK1\/2 pathway","name":"articletitle","label":"Article Title"},{"value":"Microvascular Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mvr.2022.104401","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104401"}}